Health Canada approves ALK's Ragwitek sublingual allergy immunotherapy tablets for paediatric patients with ragweed allergy


22 December 2020 - With the indication expanded to paediatric patients, ALK Canada now provides adults and children a SLIT tablet option to treat allergies to ragweed pollen, one of the most common allergens found in the provinces of Ontario and Quebec.

Today ALK, a global, research-driven pharmaceutical company, announced that Health Canada has approved once-daily Ragwitek (standardised allergen extract, Short Ragweed (Ambrosia artemisiifolia) sublingual tablet) for the treatment of moderate to severe ragweed pollen allergies in children age five and older. 

RAGWITEK had received Health Canada approval for adult use in 2014.

Read Alk-Abello press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , Medicine , Paediatrics